<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Quest Diagnostics Incorporated — News on 6ix</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated</link>
<description>Latest news and press releases for Quest Diagnostics Incorporated on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quest-diagnostics-incorporated" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355d9378dffbe2df0ecd18.webp</url>
<title>Quest Diagnostics Incorporated</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated</link>
</image>
<item>
<title>Quest Diagnostics Prices $500 Million of Senior Notes</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-prices-dollar500-million-of-senior-notes</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-prices-dollar500-million-of-senior-notes</guid>
<pubDate>Mon, 27 Apr 2026 20:10:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement.</description>
</item>
<item>
<title>Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026</guid>
<pubDate>Tue, 21 Apr 2026 10:47:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>Digi Power X Signs First AI Revenue Contract - $19.6 Million, 24-Month SubQ AI Agreement, Validating Operational Launch of AI Factory</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-signs-first-ai-revenue-contract-dollar196-million-24-month-subq-ai-agreement-validating-operational-launch-of-ai-factory-2</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-signs-first-ai-revenue-contract-dollar196-million-24-month-subq-ai-agreement-validating-operational-launch-of-ai-factory-2</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>MIAMI, FL / ACCESS Newswire / April 20, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) (the "Company" and "Digi Power X"), a Miami-based AI infrastructure operator, today announced that it has entered into a bare metal GPU rental agreement ...</description>
</item>
<item>
<title>City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/city-of-hope-to-evaluate-quest-diagnostics-haystack-mrdr-for-guiding-patient-management-in-multiple-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/city-of-hope-to-evaluate-quest-diagnostics-haystack-mrdr-for-guiding-patient-management-in-multiple-cancers</guid>
<pubDate>Thu, 16 Apr 2026 13:00:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, is implementing Haystack MRD®, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian and prostat</description>
</item>
<item>
<title>Digi Power X Enters into Amended and Restated Sales Agreement</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-enters-into-amended-and-restated-sales-agreement-2</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-enters-into-amended-and-restated-sales-agreement-2</guid>
<pubDate>Thu, 09 Apr 2026 21:15:00 GMT</pubDate>
<description>MIAMI, FL / ACCESS Newswire / April 9, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(CboeCanada:DGX) (the "Company"), an innovative energy infrastructure company pivoting into AI data centers and GPU-as-a-Service, announces that it has entered into an amended ...</description>
</item>
<item>
<title>Digi Power X Reports Fiscal Year 2025 Financial Results</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-reports-fiscal-year-2025-financial-results-3</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-reports-fiscal-year-2025-financial-results-3</guid>
<pubDate>Tue, 31 Mar 2026 23:28:00 GMT</pubDate>
<description>Digi Power X Completes Initial Pivot to AI Infrastructure: Zero Debt, $93M Liquid, 400MW Capacity Pipeline This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus ...</description>
</item>
<item>
<title>Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-to-release-first-quarter-financial-results-on-april-21-2026</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-to-release-first-quarter-financial-results-on-april-21-2026</guid>
<pubDate>Thu, 19 Mar 2026 14:00:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.</description>
</item>
<item>
<title>Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics' Providers</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/helio-genomics-to-make-heliolivertm-cancer-test-accessible-to-quest-diagnostics-providers</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/helio-genomics-to-make-heliolivertm-cancer-test-accessible-to-quest-diagnostics-providers</guid>
<pubDate>Wed, 18 Mar 2026 12:42:00 GMT</pubDate>
<description>Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today announced an agreement with Quest Diagnostics, a leading provider of diagnostic information services, to make HelioLiver™, Helio Genomics' innovative blood-based early detection test for Hepatocellular Carcinoma (HCC), widely available to physicians and patients through Quest's extensive U.S. network. The test aims to help power earlier intervention in patients who are at risk of developing HCC, the most commo</description>
</item>
<item>
<title>Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-elects-timothy-wentworth-former-ceo-of-walgreens-boots-alliance-evernorth-health-services-and-express-scripts-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-elects-timothy-wentworth-former-ceo-of-walgreens-boots-alliance-evernorth-health-services-and-express-scripts-to-board-of-directors</guid>
<pubDate>Thu, 12 Mar 2026 20:07:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members.</description>
</item>
<item>
<title>Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics-1</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics-1</guid>
<pubDate>Tue, 10 Mar 2026 12:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., March 10, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States.</description>
</item>
<item>
<title>Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-introduces-ai-companion-to-help-patients-understand-and-act-on-lab-test-results</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-introduces-ai-companion-to-help-patients-understand-and-act-on-lab-test-results</guid>
<pubDate>Mon, 02 Mar 2026 14:02:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.</description>
</item>
<item>
<title>Digi Power X Graduates to Cboe Canada</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-graduates-to-cboe-canada-2</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/digi-power-x-graduates-to-cboe-canada-2</guid>
<pubDate>Fri, 27 Feb 2026 15:00:00 GMT</pubDate>
<description>TORONTO, February 27, 2026--Digi Power X Inc. has graduated from the venture markets and is now listed under the symbol DGX on Cboe Canada,.</description>
</item>
<item>
<title>Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-names-benjamin-beauvalot-senior-vice-president-chief-strategy-and-manda-officer</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-names-benjamin-beauvalot-senior-vice-president-chief-strategy-and-manda-officer</guid>
<pubDate>Thu, 26 Feb 2026 13:24:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer.</description>
</item>
<item>
<title>Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-to-speak-at-the-leerink-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-to-speak-at-the-leerink-2026-global-healthcare-conference</guid>
<pubDate>Wed, 25 Feb 2026 15:00:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time.</description>
</item>
<item>
<title>Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-reports-fourth-quarter-114700868</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-reports-fourth-quarter-114700868</guid>
<pubDate>Tue, 10 Feb 2026 11:47:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-increases-dividend-7-113300933</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-increases-dividend-7-113300933</guid>
<pubDate>Tue, 10 Feb 2026 11:33:00 GMT</pubDate>
<description>Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.</description>
</item>
<item>
<title>Cleveland Diagnostics Names Jack Kenny as Chairman of the Board</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/cleveland-diagnostics-names-jack-kenny-as-chairman-of-the-board</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/cleveland-diagnostics-names-jack-kenny-as-chairman-of-the-board</guid>
<pubDate>Thu, 05 Feb 2026 15:09:00 GMT</pubDate>
<description>CLEVELAND, February 05, 2026--Cleveland Diagnostics Names Jack Kenny as Chairman of the Board</description>
</item>
<item>
<title>Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-launches-novel-flow-135200235</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-launches-novel-flow-135200235</guid>
<pubDate>Mon, 02 Feb 2026 13:52:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting bet</description>
</item>
<item>
<title>Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-named-fortunes-worlds-193500524</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/quest-diagnostics-named-fortunes-worlds-193500524</guid>
<pubDate>Wed, 21 Jan 2026 19:35:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year.</description>
</item>
<item>
<title>Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect</title>
<link>https://6ix.com/company/quest-diagnostics-incorporated/news/sonora-quest-and-laboratory-sciences-of-arizona-announce-jennifer-erickson-as-ceo-elect</link>
<guid isPermaLink="true">https://6ix.com/company/quest-diagnostics-incorporated/news/sonora-quest-and-laboratory-sciences-of-arizona-announce-jennifer-erickson-as-ceo-elect</guid>
<pubDate>Thu, 15 Jan 2026 14:00:00 GMT</pubDate>
<description>Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership.</description>
</item>
</channel>
</rss>